Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience

被引:27
作者
Momose, Mami [1 ]
Asahina, Akihiko [1 ]
Umezawa, Yoshinori [1 ]
Nakagawa, Hidemi [1 ]
机构
[1] Jikei Univ, Dept Dermatol, Sch Med, Tokyo, Japan
关键词
biologics; efficacy; psoriasis; safety; secukinumab; SEVERE PLAQUE PSORIASIS; MODERATE; PHASE-3;
D O I
10.1111/1346-8138.14145
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Secukinumab is a fully human monoclonal antibody that can selectively neutralize interleukin-17A, and its excellent efficacy has been demonstrated in clinical trials for psoriasis. The aim of our study is to assess long-term efficacy and safety of secukinumab for 52 weeks in real-world clinical practise in our facility. A total of 83 patients (71 with psoriasis vulgaris and 12 with psoriatic arthritis) were included, and 49 of them were bio-switched patients. Psoriasis Area and Severity Index (PASI) 75 and PASI-90 responses were 80% and 64% at week 12, 77% and 65% at week 24, and 76% and 58% at week 52, respectively. No significant differences were observed in efficacy between bio-naive and bio-switched patients. Arthralgia showed improvement by week 12 in all patients with psoriatic arthritis with a reduction of serum C-reactive protein level. Treatment was discontinued in 22% (18/83), including eight patients with no improvement or exacerbation of cutaneous manifestations, one patient with new onset of arthritis and two patients with transient infection. Overall, secukinumab showed a sustained clinical response with an acceptable safety profile through week 52 in Japanese psoriatic patients.
引用
收藏
页码:318 / 321
页数:4
相关论文
共 10 条
  • [1] Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations
    Gossec, Laure
    Coates, Laura C.
    de Wit, Maarten
    Kavanaugh, Arthur
    Ramiro, Sofia
    Mease, Philip J.
    Ritchlin, Christopher T.
    van der Heijde, Desiree
    Smolen, Josef S.
    [J]. NATURE REVIEWS RHEUMATOLOGY, 2016, 12 (12) : 743 - 750
  • [2] Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study
    Imafuku, Shinichi
    Honma, Masaru
    Okubo, Yukari
    Komine, Mayumi
    Ohtsuki, Mamitaro
    Morita, Akimichi
    Seko, Noriko
    Kawashima, Naoko
    Ito, Saori
    Shima, Tomohiro
    Nakagawa, Hidemi
    [J]. JOURNAL OF DERMATOLOGY, 2016, 43 (09) : 1011 - 1017
  • [3] Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
    Langley, Richard G.
    Elewski, Boni E.
    Lebwohl, Mark
    Reich, Kristian
    Griffiths, Christopher E. M.
    Papp, Kim
    Puig, Lluis
    Nakagawa, Hidemi
    Spelman, Lynda
    Sigurgeirsson, Bardur
    Rivas, Enrique
    Tsai, Tsen-Fang
    Wasel, Norman
    Tyring, Stephen
    Salko, Thomas
    Hampele, Isabelle
    Notter, Marianne
    Karpov, Alexander
    Helou, Silvia
    Papavassilis, Charis
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (04) : 326 - 338
  • [4] Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
    McInnes, Iain B.
    Mease, Philip J.
    Kirkham, Bruce
    Kavanaugh, Arthur
    Ritchlin, Christopher T.
    Rahman, Proton
    Van der Heijde, Desiree
    Landewe, Robert
    Conaghan, Philip G.
    Gottlieb, Alice B.
    Richards, Hanno
    Pricop, Luminita
    Ligozio, Gregory
    Patekar, Manmath
    Mpofu, Shephard
    [J]. LANCET, 2015, 386 (9999) : 1137 - 1146
  • [5] Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch
    Ohtsuki, Mamitaro
    Morita, Akimichi
    Igarashi, Atsuyuki
    Imafuku, Shinichi
    Tada, Yayoi
    Fujita, Hiroyuki
    Fujishige, Ayako
    Yamaguchi, Masako
    Teshima, Rie
    Tani, Yumiko
    Nakagawa, Hidemi
    [J]. JOURNAL OF DERMATOLOGY, 2017, 44 (10) : 1105 - 1111
  • [6] Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study
    Ohtsuki, Mamitaro
    Morita, Akimichi
    Abe, Masatoshi
    Takahashi, Hidetoshi
    Seko, Noriko
    Karpov, Alexander
    Shima, Tomohiro
    Papavassilis, Charis
    Nakagawa, Hidemi
    [J]. JOURNAL OF DERMATOLOGY, 2014, 41 (12) : 1039 - 1046
  • [7] Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis
    Reich, K.
    Blauvelt, A.
    Armstrong, A.
    Langley, R. G.
    Fox, T.
    Huang, J.
    Papavassilis, C.
    Liang, E.
    Lloyd, P.
    Bruin, G.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (03) : 752 - 758
  • [8] Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study
    Rich, P.
    Sigurgeirsson, B.
    Thaci, D.
    Ortonne, J. -P.
    Paul, C.
    Schopf, R. E.
    Morita, A.
    Roseau, K.
    Harfst, E.
    Guettner, A.
    Machacek, M.
    Papavassilis, C.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (02) : 402 - 411
  • [9] Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)
    Thaci, D.
    Humeniuk, J.
    Frambach, Y.
    Bissonnette, R.
    Goodman, J. J.
    Shevade, S.
    Gong, Y.
    Papavassilis, C.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (03) : 777 - 787
  • [10] Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
    van de Kerkhof, Peter C. M.
    Griffiths, Christopher E. M.
    Reich, Kristian
    Leonardi, Craig L.
    Blauvelt, Andrew
    Tsai, Tsen-Fang
    Gong, Yankun
    Huang, Jiaqing
    Papavassilis, Charis
    Fox, Todd
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (01) : 83 - +